Companies TG Therapeutics, Inc
TG Therapeutics (TGTX): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me TG Therapeutics, Inc’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO pay, last three years
- $15,837,559FY2023
- $18,752,897FY2024
- $25,571,250FY2025
CEO total pay was $25,571,250 in fiscal 2025, up from $18,752,897 in fiscal 2024.
FY2025: salary $875,000 · bonus $0 · stock awards $23,550,000 · option awards $0
Executives and directors
Frequently asked questions
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Michael Weiss | $875,000 | $0 | $23,550,000 | $0 | $1,146,250 | $0 | $0 | $25,571,250 |
| Chairman, Chief Executive Officer and President | ||||||||
| Sean Power | 500,000 | 0 | 2,919,875 | 0 | 327,500 | 0 | 21,000 | 3,768,375 |
| Chief Financial Officer, Treasurer and Corporate Secretary | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Michael Weiss | $25,571,250 | $18,752,897 | $15,837,559 | ↑ +6,818,353 |
| Sean Power | 3,768,375 | 2,254,350 | 1,867,378 | ↑ +1,514,025 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
Our executive compensation programs are designed to motivate our employees to create long-term sustained stockholder value by acquiring, developing and commercializing novel treatments for B-cell diseases. The Compensation Committee's executive compensation philosophy is guided by the following objectives: to attract, retain, motivate and reward highly qualified employees; to align the interests of our NEOs with those of our stockholders, including through equity-based compensation and performance-based incentives; to link a significant portion of compensation to the achievement of the Company performance objectives; to recognize individual contributions while promoting accountability and shared performance goals; and to support a pay for performance framework that emphasizes long-term value creation.
| CEO STI target (% of salary) | 100% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Compensia, Inc. |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | True |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Sean Power | RSU | 2025-01-29 | — | — | 87,500 | — | $2,919,875 |
| Michael Weiss | RSU | 2025-01-29 | — | — | 750,000 | — | 23,550,000 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Sean Power | $2,919,875 | $0 | $0 | 0.0% |
| Michael Weiss | 23,550,000 | 0 | 0 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Sean Power | RSU | 42,500 | — | $1,266,925 |
| Sean Power | RSU | 56,250 | — | 1,676,813 |
| Sean Power | RSU | 87,500 | — | 2,608,375 |
| Michael Weiss | Option | 633,334 | 7 | — |
| Michael Weiss | RSU | 750,000 | — | 22,357,500 |
| Michael Weiss | RSU | 985,000 | — | 29,362,850 |
| Michael Weiss | RSU | 1,001,908 | — | 29,866,877 |
| Michael Weiss | RSU | 1,080,770 | — | 32,217,754 |
| Michael Weiss | RSU | 1,556,029 | — | 46,385,224 |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Laurence N. CharneyIndependent · Lead Independent Director · Audit (Chair) · Compensation | $143,000 | $800,017 | $0 | $0 | $0 | $943,017 |
| Kenneth HobermanIndependent · Audit · Compensation (Chair) | 101,000 | 550,012 | 0 | 0 | 0 | 651,012 |
| Daniel HumeIndependent · Audit · Compensation · Nominating and Corporate Governance | 96,750 | 550,012 | 0 | 0 | 0 | 646,762 |
| Yann EchelardIndependent · Audit · Compensation · Nominating and Corporate Governance | 96,750 | 550,012 | 0 | 0 | 0 | 646,762 |
| Sagar Lonial, MDIndependent · Compensation · Nominating and Corporate Governance (Chair) | 94,250 | 550,012 | 0 | 0 | 0 | 644,262 |
| Michael S. WeissEmployee director · Board Chair | 0 | 0 | 0 | — | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $70,000 |
|---|---|
| Annual equity retainer | $550,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 25,000 / 20,000 / 15,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $531,750 |
| Equity awards (grant-date value) | $3,000,065 |
| All other compensation | $0 |
| Total cost of the board | $3,531,815 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names TG Therapeutics as a peer
Companies that benchmark against TGTX
13 companies name TGTX as a compensation peer
- ADMA BIOLOGICS, INC.ADMAFY2025
- AGIOS PHARMACEUTICALS, INC.AGIOFY2025
- ARDELYX, INC.ARDXFY2025
- ARS Pharmaceuticals, Inc.SPRYFY2025
- AVADEL PHARMACEUTICALS PLCAVDLFY2024
- BICYCLE THERAPEUTICS PLCBCYCFY2024
- Crinetics Pharmaceuticals, Inc.CRNXFY2025
- ImmunityBio, Inc.IBRXFY2025
- Immunocore Holdings plcIMCRFY2025
- Krystal Biotech, Inc.KRYSFY2025
- RHYTHM PHARMACEUTICALS, INC.RYTMFY2025
- SpringWorks Therapeutics, Inc.SWTXFY2024
- Syndax Pharmaceuticals IncSNDXFY2025
- Verona Pharma plcVRNAFY2024
Each company listed discloses TGTX in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named TGTX in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Peer reciprocity
The companies TG Therapeutics, Inc names as compensation peers that name it back in their own disclosed peer groups.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | TG Therapeutics, Inc | 2025 | Michael Weiss | $875,000 | $23,550,000 | $0 | $1,146,250 | $25,571,250 |
| 2 | Halozyme Therapeutics | 2025 | Helen Torley | 1,000,000 | 19,350,145 | 1,650,014 | 1,147,500 | 23,166,223 |
| 3 | Madrigal Pharmaceuticals, Inc. | 2025 | Bill Sibold | 918,531 | 12,297,850 | 4,537,146 | 1,438,814 | 19,206,341 |
| 4 | SpringWorks Therapeutics | 2024 | Saqib Islam | 760,000 | 7,899,760 | 6,689,100 | 798,000 | 16,153,317 |
| 5 | Corcept Therapeutics | 2025 | Joseph Belanoff | 1,182,333 | 0 | 12,907,718 | 0 | 15,303,551 |
| 6 | BridgeBio Pharma | 2025 | Neil Kumar | 1,044,000 | 10,606,275 | 1,874,992 | 0 | 14,944,585 |
| 7 | Insmed | 2025 | William Lewis | 854,550 | 2,999,940 | 9,000,033 | 1,495,463 | 14,467,393 |
| 8 | Blueprint Medicines Corporation | 2024 | Kathryn Haviland | 821,363 | 7,472,480 | 4,315,144 | 854,217 | 13,477,004 |
| 9 | Neurocrine Biosciences | 2025 | Kyle Gano | 920,000 | 5,750,023 | 5,750,006 | 0 | 13,448,935 |
| 10 | Ionis Pharmaceuticals | 2025 | Brett Monia | 1,051,776 | 8,444,838 | 1,438,105 | 0 | 13,350,777 |
| 11 | Ultragenyx Pharmaceutical, Inc. | 2025 | Emil Kakkis | 861,100 | 8,364,938 | 1,847,356 | 299,663 | 11,405,535 |
| 12 | Vericel Corporation | 2025 | Dominick Colangelo | 860,000 | 3,964,630 | 5,456,287 | 860,000 | 11,156,368 |
| 13 | Apellis Pharmaceuticals, Inc. | 2024 | Cedric Francois | 793,193 | 4,779,832 | 4,787,768 | 0 | 10,957,451 |
| 14 | Krystal Biotech | 2025 | Krish Krishnan | 846,167 | 4,104,825 | 4,675,093 | 0 | 10,442,485 |
| 15 | Axsome Therapeutics | 2025 | Herriot Tabuteau | 835,000 | 5,533,554 | 2,833,237 | 876,750 | 10,283,492 |
| 16 | Adma Biologics | 2025 | Adam Grossman | 925,000 | 4,049,994 | 4,049,998 | 1,156,250 | 10,237,326 |
| 17 | Amicus Therapeutics, Inc. | 2024 | Bradley Campbell | 767,308 | 4,990,365 | 2,105,627 | 0 | 8,526,943 |
| 18 | Acadia Pharmaceuticals, Inc. | 2025 | Catherine Owen Adams | 930,000 | 3,240,558 | 3,234,797 | 818,559 | 8,256,518 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| TG Therapeutics, Inc | 131% | RSU 100 | No | Compensia, Inc. |
| Acadia Pharmaceuticals, Inc. | 110% | Options 50 · PSU 25 · RSU 25 | Yes | Frederic W. Cook & Co., Inc. (FW Cook) |
| Adma Biologics | 125% | RSU 50 · Options 50 | not disclosed | Pay Governance LLC |
| Amicus Therapeutics, Inc. | not disclosed | Option 33 · RSU 33 · PRSU 33 | Yes — TSR Goal | Pay Governance |
| Apellis Pharmaceuticals, Inc. | 90.74% | RSU 50 · PSU 50 | not disclosed | Pay Governance |
| Axsome Therapeutics | 150% | RSU 33 · Options 33 · PSU 33 | No | Frederic W. Cook & Co., Inc. |
| Blueprint Medicines Corporation | 130% | RSU 37 · Options 32 · PSU 31 | Yes — Relative Total Stockholder Return (rTSR) | Aon |
| BridgeBio Pharma | 135% | RSU 50 · PSU 35 · Options 15 | No | Aon Talent Solutions |
| Corcept Therapeutics | Dr. Belanoff: 100%; Dr. Guyer: 120%; Mr. Maduck: 80%; Mr. Mokari: 100%; Mr. Robb: 100%% | Stock Options 100 | not disclosed | not disclosed |
| Halozyme Therapeutics | 127.5% | PSU 50 · RSU 35 · Option 15 | No | F.W. Cook & Co., Inc. |
| Insmed | 175% | Options 75 · RSU 25 | No | Willis Towers Watson (WTW) |
| Ionis Pharmaceuticals | not disclosed | PRSU 40 · Option 30 · RSU 30 | Yes — Relative TSR | Aon |
| Krystal Biotech | 100% | not disclosed | not disclosed | Compensia, Inc. |
| Madrigal Pharmaceuticals, Inc. | not disclosed | PSU 33.33 · RSU 33.33 · Option 33.33 | Yes — Relative TSR vs Nasdaq Biotechnology Index | Compensia, Inc. |
| Neurocrine Biosciences | 105% | Option 50 · PRSU 30 · RSU 20 | No | Frederic W. Cook & Co., Inc. |
| SpringWorks Therapeutics | 140% | not disclosed | Yes — Relative Total Shareholder Return (TSR) | Aon |
| Ultragenyx Pharmaceutical, Inc. | 44% | PSU 60 · RSU 20 · Options 20 | Yes — Relative TSR | Aon's Human Capital Solutions Practice |
| Vericel Corporation | 100% | Options 58 · RSU 42 | not disclosed | FW Cook |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-11 | 31,905,837 | 48,858,169 | 668,903 | 39.18% | Failed |
| 2025 | 2025-06-12 | 47,864,737 | 39,988,402 | 383,906 | 54.25% | Passed |
| 2024 | 2024-06-14 | 42,346,581 | 31,019,084 | 2,748,761 | 55.64% | Passed |
| 2023 | 2023-06-14 | 26,007,780 | 43,450,323 | 332,453 | 37.44% | Failed |
| 2022 | 2022-06-16 | 25,817,915 | 61,157,912 | 509,014 | 29.68% | Failed |
| 2019 | 2019-06-13 | 18,680,856 | 14,124,362 | 7,950,081 | 56.94% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-06-11 | 39.18%a |
| 2025 | 2025-06-12 | 54.25%b |
| 2024 | 2024-06-14 | 55.64%c |
a. Approved under the standard stated in the filing — “Abstentions will have the same effect as a negative vote on this proposal.”.
b. Approved under the standard stated in the filing — “Abstentions will have the same effect as a negative vote on this proposal.”.
c. Approved under the standard stated in the filing — “Abstentions will have the same effect as a negative vote on this proposal.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | 67 : 1 |
|---|---|
| CEO total compensation | $25,571,250 |
| Median employee compensation | — |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Yann Echelard | Director | 2026-06-11 | A | 8,325 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Daniel Hume | Director | 2026-06-11 | A | 8,325 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kenneth Hoberman | Director | 2026-06-11 | A | 8,325 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Laurence N. Charney | Director | 2026-06-11 | A | 8,325 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sagar Lonial, MD | Director | 2026-06-11 | A | 8,325 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Laurence N. Charney | Director | 2026-08-06 | D | 5,100 | 0 | 0 | Common | Form 4 ↗ |
| Laurence N. Charney | Director | 2026-08-07 | D | 450 | 0 | 0 | Common | Form 4 ↗ |
| Laurence N. Charney | Director | 2026-08-07 | D | 500 | 0 | 0 | Common | Form 4 ↗ |
| Laurence N. Charney | Director | 2026-09-10 | D | 5,000 | 55 | 274,800 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (47 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Michael Weiss. DEF 14A, filed 2026-04-30. Section “Summary Compensation Table” · page 29. As printed: 25,571,250. View filing ↗
- Section 01, Sean Power. DEF 14A, filed 2026-04-30. Section “Summary Compensation Table” · page 29. As printed: 3,768,375. View filing ↗
- Section 03, Sean Power RSU. DEF 14A, filed 2026-04-30. Section “EXECUTIVE COMPENSATION &” · grants of plan-based awards table. View filing ↗
- Section 03, Michael Weiss RSU. DEF 14A, filed 2026-04-30. Section “Grants of Plan-Based Awards For Fiscal Year 2025” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2026-04-30. Section “CEO Pay Ratio”. As printed: 67 : 1. View filing ↗
- Section 08, Laurence N. Charney. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 943,017. View filing ↗
- Section 08, Kenneth Hoberman. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 651,012. View filing ↗
- Section 08, Daniel Hume. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 646,762. View filing ↗
- Section 08, Yann Echelard. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 646,762. View filing ↗
- Section 08, Sagar Lonial, MD. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 644,262. View filing ↗
- Section 08, Michael S. Weiss. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Yann Echelard 2026-06-11. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Daniel Hume 2026-06-11. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kenneth Hoberman 2026-06-11. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Laurence N. Charney 2026-06-11. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sagar Lonial, MD 2026-06-11. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Laurence N. Charney 2026-08-06. Form 4, filed 2026-08-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Laurence N. Charney 2026-08-07. Form 4, filed 2026-08-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Laurence N. Charney 2026-08-07. Form 4, filed 2026-08-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Laurence N. Charney 2026-09-10. Form 4, filed 2026-09-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-06-12. Item 5.07 · say-on-pay result. As reported: 39.18% (votes for as printed: 31,905,837). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-06-13. Item 5.07 · say-on-pay result. As reported: 54.25% (votes for as printed: 47,864,737). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-06-17. Item 5.07 · say-on-pay result. As reported: 55.64% (votes for as printed: 42,346,581). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 531,750 + equity 3,000,065 + all other 0 = 3,531,815, summed across the director compensation table rows.
- TG Therapeutics, Inc (subject), Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in TG Therapeutics, Inc's own proxy. As printed: 25,571,250. View filing ↗
- Halozyme Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-03-23. CEO total compensation as printed in Halozyme Therapeutics's own proxy. As printed: 23,166,223. View filing ↗
- Madrigal Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Madrigal Pharmaceuticals, Inc.'s own proxy. As printed: 19,206,341. View filing ↗
- SpringWorks Therapeutics, Section 10b CEO total. DEF 14A, filed 2025-04-04. CEO total compensation as printed in SpringWorks Therapeutics's own proxy. As printed: 16,153,317. View filing ↗
- Corcept Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-17. CEO total compensation as printed in Corcept Therapeutics's own proxy. As printed: 15,303,551. View filing ↗
- BridgeBio Pharma, Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in BridgeBio Pharma's own proxy. As printed: 14,944,585. View filing ↗
- Insmed, Section 10b CEO total. DEF 14A, filed 2026-04-01. CEO total compensation as printed in Insmed's own proxy. As printed: 14,467,393. View filing ↗
- Blueprint Medicines Corporation, Section 10b CEO total. DEF 14A, filed 2025-04-24. CEO total compensation as printed in Blueprint Medicines Corporation's own proxy. As printed: 13,477,004. View filing ↗
- Neurocrine Biosciences, Section 10b CEO total. DEF 14A, filed 2026-04-15. CEO total compensation as printed in Neurocrine Biosciences's own proxy. As printed: 13,448,935. View filing ↗
- Ionis Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Ionis Pharmaceuticals's own proxy. As printed: 13,350,777. View filing ↗
- Ultragenyx Pharmaceutical, Inc., Section 10b CEO total. DEF 14A, filed 2026-03-27. CEO total compensation as printed in Ultragenyx Pharmaceutical, Inc.'s own proxy. As printed: 11,405,535. View filing ↗
- Vericel Corporation, Section 10b CEO total. DEF 14A, filed 2026-03-19. CEO total compensation as printed in Vericel Corporation's own proxy. As printed: 11,156,368. View filing ↗
- Apellis Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2025-04-23. CEO total compensation as printed in Apellis Pharmaceuticals, Inc.'s own proxy. As printed: 10,957,451. View filing ↗
- Krystal Biotech, Section 10b CEO total. DEF 14A, filed 2026-04-03. CEO total compensation as printed in Krystal Biotech's own proxy. As printed: 10,442,485. View filing ↗
- Axsome Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Axsome Therapeutics's own proxy. As printed: 10,283,492. View filing ↗
- Adma Biologics, Section 10b CEO total. DEF 14A, filed 2026-04-15. CEO total compensation as printed in Adma Biologics's own proxy. As printed: 10,237,326. View filing ↗
- Amicus Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2025-04-24. CEO total compensation as printed in Amicus Therapeutics, Inc.'s own proxy. As printed: 8,526,943. View filing ↗
- Acadia Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Acadia Pharmaceuticals, Inc.'s own proxy. As printed: 8,256,518. View filing ↗
- Section 10a, SpringWorks Therapeutics reciprocity. DEF 14A. SpringWorks Therapeutics names TG Therapeutics, Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Krystal Biotech reciprocity. DEF 14A. Krystal Biotech names TG Therapeutics, Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, ADMA Biologics reciprocity. DEF 14A. ADMA Biologics names TG Therapeutics, Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗